Abstract: Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis, with variable clinical features, nonspecific histopathology and multifactorial pathogenesis, posing a challenging diagnosis for the dermatologist. Pyoderma gangrenosum is a diagnosis of exclusion and should be included in the differential diagnoses of the verrucous syndrome. We report a granulomatous variant affecting the face.
Pyoderma gangrenosum (PG) is an uncommon entity with a diverse clinical spectrum and nonspecific histopathology. Awareness of its various manifestations, as well as its differential diagnoses, is essential for early therapy to reduce morbidity. On initial approach, PG should also be remembered as a clinical hypothesis of the verrucous syndrome.
We report a 72-year-old male patient who sought care for painful facial lesions that had evolved over six months. He reported that the first lesion appeared in the right temporal region and had rapidly and progressively worsened. Subsequently, a smaller lesion, though similar to the first one, appeared in the left temporal region.
The patient was a smoker (more than 30 pack-years ), previously healthy, and denied the use of medications. The histopathology is nonspecific and depends on the subtype of the lesion and on the duration of evolution, but it contributes to the exclusion of other diseases. There is neutrophilic infiltration in recent lesions, and necrosis associated with fibrosis in the chronic lesions, as well as a granulomatous process; however, these findings are not pathognomonic.
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The diagnosis is often challenging and delayed, requiring clinical and pathological correlation; hence the importance of familiarity with the differential diagnoses and morphological aspects. It should be noted that PG may be included as a differential diagnosis of the verrucous syndrome, classically recognized by the mnemonic term "PLECT" (paracoccidioidomycosis, leishmaniasis, sporotrichosis, chromomycosis, tuberculosis). Histoplasmosis should also be considered.
Negative screening investigation for systemic disease prompted us to consider the idiopathic nature of PG in our patient.
Facial involvement was striking and the excellent response to both steroid and sulfonamide should be highlighted. Given the distinct verrucous aspect that granulomatous PG can present (which has long been described in the literature), could a second "P" be added The most effective treatment for PG is systemic corticotherapy, which can be administered through pulse therapy for more severe cases. Other medications with antineutrophilic potential, such as dapsone and other sulfonamides, and clofazimine can also be used, as in the present case. Cyclosporin, azathioprine, and infliximab have also been employed as alternative drugs in refractory cases. 6 q
